Cadila Healthcare gets EIR for formulations manufacturing facility at Baddi

29 May 2020 Evaluate

Cadila Healthcare has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its formulations manufacturing facility located at Baddi, India. The EIR report stated that the classification of the facility is ‘No Action Indicated (NAI)’. The USFDA had conducted an inspection at the facility from March 2, 2020 to March 9, 2020 and the audit had ended with nil observations.

Cadila Healthcare is an Indiabased pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

914.45 -3.90 (-0.42%)
18-Dec-2025 10:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1749.80
Dr. Reddys Lab 1264.00
Cipla 1495.35
Zydus Lifesciences 914.45
Lupin 2105.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×